Cite

HARVARD Citation

    Schuetze, S. et al. (2016). SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma. Cancer. 122 (6), pp. 868-874. [Online]. 
  
Back to record